BiotechTube

HR021618 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pain After Abdominal Surgery

Conditions

Pain After Abdominal Surgery

Trial Timeline

Apr 12, 2021 → Jul 15, 2021

NCT ID
NCT04811053

About HR021618 + Placebo

HR021618 + Placebo is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Pain After Abdominal Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT04811053. Target conditions include Pain After Abdominal Surgery.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04811053Phase 2Completed

Competing Products

20 competing products in Pain After Abdominal Surgery

See all competitors
ProductCompanyStageHype Score
PRF110- oily solution (Ropivacaine)PainReformPhase 2
44
PRF110PainReformPhase 2
44
PRF-108 + Placebo + Ropivacaine + PRF-110PainReformPhase 1/2
33
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
25
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
TRV130TrevenaPhase 3
69
TRV130 + Morphine + PlaceboTrevenaPhase 2
44
TRV130TrevenaPhase 2
44
LY3556050 + PlaceboEli LillyPhase 2
52
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
80
Nanoformed Piroxicam IR Tablet + Felden (piroxicam) Tablets + Brexidol (piroxicam) TabletsNanoform FinlandPhase 1
28
0.75% bupivacaine + .75% bupivacaine + .75% bupivacaineSI-BONEApproved
77
LY3526318 + PlaceboEli LillyPhase 2
52
LY3857210 + PlaceboEli LillyPhase 2
52
OK-101 0.05% + OK-101 0.1% + PlaceboOKYO PharmaPhase 2
44
YHD1119 + LyricaYuhanPhase 1
33
YHD1119 + LyricaYuhanPhase 1
33
YHD1119 + LyricaYuhanPhase 3
77
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85